Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: PPAR gamma agonist Tumor Cancer Antineoplastic Agent Respiratory Tract Neoplasms Erlotinib Protein Kinase Inhibitors Neoplasms
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with erlotinib.

Detailed description:

Arms:
arm 1: Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily

Interventions: intervention 1: CS-7017 intervention 2: Erlotinib
Intervention descriptions: intervention 1: CS-7017 from 0.25 mg to 0.50 mg twice daily intervention 2: Erlotinib 150 mg once daily

Protocol document: